Human thrombin topical - Grifols

Drug Profile

Human thrombin topical - Grifols

Alternative Names: Topical Thrombin (Human) Grifols

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Grifols
  • Class Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Serine endopeptidases
  • Mechanism of Action Blood coagulation stimulants; Thrombin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Surgical blood loss

Most Recent Events

  • 23 Mar 2017 No recent reports of development identified - Phase-II for Surgical blood loss (Prevention) in USA (Topical)
  • 01 Nov 2015 Grifols completes a phase II trial for Surgical blood loss (Prevention) in USA (NCT02014402)
  • 17 Feb 2014 Phase-II clinical trials in Surgical blood loss (prevention) in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top